Skip to content

Fat Grafting Technique for Fecal Incontinence

Evaluation of Fat Grafting Technique Using Autologous Micro-fragmented Autologous Adipose Tissue Lipogems in Fecal Incontinence

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03882632
Enrollment
10
Registered
2019-03-20
Start date
2019-04-11
Completion date
2021-12-31
Last updated
2020-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Incontinence

Brief summary

Fecal Incontinence affects an estimated 2-20% of the general population, and up to 50% of the elderly and institutionalized population. Patients with incontinence tend to suffer in silence; they often do not seek help because of embarrassment and stigma. They often become confined to their homes because they are afraid of having an accident. Although this is not a life-threatening condition, the psychological, emotional, and social impact can be devastating.

Detailed description

The purpose of this study is to evaluate reconstructive lipoplasty with micro-fragmented autologous adipose tissue (Lipogems®) in female patients with fecal incontinence. Our hypothesis is that placing approximately up to 90 cc of Lipogems® will yield an effective increase in surviving material (over normal fat injection) due to the refinement of the process and result in decreased fecal incontinence over the long term. Human Adipose Tissue (Fat) possesses regenerative properties in its stromal vascular fraction (SVF). SVF contains nests of pericytes and human MSC mesenchymal stem cells). MSCs are multipotent cells (also called stromal multipotent cells), that possess the ability to differentiate into various tissues, such as bone, tendon, articular cartilage, ligaments, muscle, and fat. Upon fragmentation of adipose tissue using Lipogems®, viable elements are preserved with pericyte identity within an intact stromal vascular niche. It is hypothesized that upon trauma or disruption of this adipose tissue, the regenerative cells within the intact perivascular niche interact via micro vesicles with the microenvironment at the transplant site to promote angiogenesis, neuronal sprouting and fibroblast production thereby stimulating increased vasculature (circulation, nerve regeneration, muscle growth and tone in the urethral sphincter and in the urethral muscles). If these changes are observed, long lasting regenerative changes occur and should be long lasting versus the shorter live effects of the bulking effect by undisrupted fat tissue. This is a pilot study of 10 subjects will be treated with local injections of Lipogems® and followed for up to two years. Subjects will receive a full history and examination by a single colorectal surgeon. A clear history of their incontinence frequency, Wexner Incontinence Score, Fecal Incontinence Quality of Life Scale, surgical history, and childbirth history will be collected for all registered patients in order to categorize the study participant according to incontinence-type. All patients will undergo anal physiology testing and endoanal ultrasound. Pre and post measurements will be recorded and compared for objective evaluation. Patients will be evaluated subjectively with the Wexner incontinence Score and Fecal Incontinence Quality of Life Scale. Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally. This will be done in the procedure room or operating room with IV sedation and local anesthesia. This will all occur in the same setting on the same day.

Interventions

DEVICEFat Grafting for Fecal Incontinence

Autologous adiopse tissue harvesting/grafting using Lipogems

Sponsors

Lifespan
CollaboratorOTHER
Melanie Salerno, RN
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age: \>18 \< 65 years 2. Sex: females 3. Affected by fecal incontinence (moderate to severe) independently from the etiology and previous treatments 4. No restrictions to follow-up for 24 months after treatment 5. Willing and able to provide informed consent

Exclusion criteria

1. Present diagnosis of cancer (not in remission) 2. Patients with uncorrected rectal prolapse 3. Overflow incontinence 4. Patients with neurogenic bowel or spinal cord injuries 5. Any patients unable to give informed consent, including members of vulnerable populations 6. Patients with concomitant pelvic floor disorders, like paradoxical puborectalis contraction or pelvic floor dysfunction 7. Chronic diarrhea 8. Patients with chronic steroid use 9. Patients 17 and under 10. Anal Sepsis (abscess and/or fistula) 11. Inability to undergo the intended diagnostic tests and follow-up 12. Pregnancy 13. Diagnosis of Diabetes Mellitus 1 and 2

Design outcomes

Primary

MeasureTime frameDescription
Resolution of Fecal Incontinence Measured by patient reported outcomes on questionnaires2 yearsComparison of pre and post procedure outcomes via outcomes questionaires
Resolution of Fecal Incontinence Measured by Physical Exam2 yearsComparison of pre and post procedure outcomes via Endoanal Ultrasound and Physiology Testing

Secondary

MeasureTime frameDescription
Incident of treatment related adverse events2 yearsSite reported adverse events designated as related to treatment

Countries

United States

Contacts

Primary ContactMelanie Salerno
melanie.salerno@brownphysicians.org4014447148

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026